



Media Release

12 Mar 2013

Hugh Alsop appointed Hatchtech CEO

- *Dr Ross Macdonald returns to board as non exec director*
 - *Hugh Alsop formerly Phosphagenics VP and Acrux Business Development Director*
-

Melbourne, Australia: Specialty pharmaceutical company Hatchtech Pty Ltd is pleased to announce the appointment of former Phosphagenics Vice President Mr Hugh Alsop as the company's new Chief Executive Officer.

The resignation of Dr Macdonald as CEO follows the securing of a suitable candidate to fill this position. Dr Macdonald will step back onto the Board to resume his Non-Executive Director role. Ross' leadership took the company through a transitional period in which the company concluded a highly successful Phase 2b study and end of Phase 2 consultation with the US Food and Drug Administration (FDA) for its lead product DeOvo™, a single application topical treatment for head lice, and completed a \$6m financing to position the Company to begin its Phase 3 program this year.

Dr Macdonald has decided to resign to pursue his other interests, while remaining on the board of Hatchtech as a Non-Executive Director. Hatchtech Chairman Dr Paul Kelly stated, "We are very grateful for the contribution that Ross has made to Hatchtech over the past year as CEO and pleased he is remaining on the board as a Non-Executive Director."

Mr Alsop was formerly Vice President of Operations and Business Development at Phosphagenics Limited. His former roles include Director of Business Development at Acrux Limited from 2006-2012 where his highlight achievement was his role in the Axiron® licensing to Eli Lilly in March 2010. At the time this was the largest single product licensing deal by an Australian biotech company, with \$335 million in potential milestone payments and a significant royalty stream. Axiron was subsequently approved for use by the FDA.

Prior to Acrux, Mr Alsop was responsible for successfully expanding Sigma Pharmaceuticals' export markets in Europe and Asia completing a number of out-licensing, manufacturing and distribution agreements. He was also responsible for the commercial aspects of Sigma's contract manufacturing business, focusing on maximising existing relationships and seeking new growth opportunities. Prior to Sigma he spent eight years at Mayne Pharma (formerly Faulding Pharmaceuticals) in a variety of roles.

Dr Kelly stated, "The appointment of Hugh Alsop adds impetus to Hatchtech's pursuit of its Phase 3 development and commercialisation goals and we look forward to working closely with Hugh to achieve these outcomes."

Mr Alsop added: "I am excited to be joining Hatchtech at such a crucial time for the company. It is clear that the attributes of DeOvo will deliver best-in-class benefits to patients, and thus a compelling commercial opportunity for the prospective marketers of the product. The next twelve months will require a dedicated and focused execution of the

company's clinical, regulatory and commercial plans, and I look forward to leading this program to ensure the value of DeOvo is maximised for Hatchtech shareholders."

Hugh has over 16 years experience in the pharmaceutical industry and holds a Bachelor of Science with Honours (in Chemistry) from the University of Melbourne and an MBA from the Melbourne Business School.

Company Contact Media Inquiries:

Dr Paul Kelly
Chairman
+61 (0)2 82057379
pkelly@one-ventures.com

Mr Hugh Alsop
Chief Executive Officer
+61 (0) 439080353
halsop@hatchtech.com.au

About Hatchtech

Hatchtech Pty Ltd is an Australian specialty pharmaceutical product company developing technology for the control of invertebrate pests. The Company's lead product is DeOvo™, a class-leading head lice control agent that aims to overcome the frustrating, costly and inconvenient cycles of re-treatment experienced currently by children and their parents. The Company's investors include, GBS Venture Partners, Queensland Biotechnology Fund, Uniseed, University of Melbourne Endowment Trust, Australian Super, and OneVentures Innovation Fund. The OneVentures Innovation Fund is supported by the Australian Government through the IIF program.

Hatchtech Pty Ltd

Level 9, 278 Collins Street, Melbourne, 3000, Australia
www.hatchtech.com.au

About DeOvo™

Despite its prevalence and high cost to the community, there have been few major advances in controlling head lice infestation in recent years. Most pediculicide products have little ovicidal activity and require two treatments (approximately 7 days apart), with the second application designed to treat those lice which have hatched from eggs that survived the first treatment. Non-compliance with this regimen and the difficulty in choosing the optimal time for the second application, are major difficulties in using these products. Hatchtech's DeOvo™, a topical formulation of an inhibitor of metalloproteases, has shown both ovicidal and lousicidal activity and offers the potential for a more effective treatment following a single application.

About Pediculosis

It is estimated that 6-12 million people in the United States, mainly children aged 3-12, are infested each year with head lice (*Pediculus humanus capitis*). The direct cost of treatment is estimated at several hundreds of millions of dollars. Added to this direct economic burden are the indirect costs including missed days from school, lost work productivity by parents who stay home to treat their children and costs borne by the school itself in trying to control or prevent this problem. The total costs have been estimated to be 1 billion USD in the US alone.